Vancouver, B.C., May 9, 2018 – MYM Nutraceuticals Inc., (CSE: MYM) (the “Company” or “MYM”) is pleased to provide the following update regarding the Sublime Culture Inc. ACMPR production facility located in Laval, Quebec.

The Sublime Culture Inc. Laval facility has been completed as per ACMPR standards and guidelines. Sublime Culture submitted the Confirmation of Readiness for a License to Health Canada on December 15, 2017. Since this time, Sublime has worked closely with Health Canada to ensure that all further inquiries into the project have been satisfied. The Sublime Culture ACMPR license application is currently in the queue awaiting final review from Health Canada.

“The Company is satisfied that Sublime Culture Inc. has provided Health Canada with all the necessary information in order for them to move ahead with the license application,” said Rob Gietl, CEO of MYM. “The completedLaval facility is currently 10,000 square feet. Phase two of the project will see the growing capacity increased to 37,000 square feet by the end of 2018. We have been advised by Health Canada that our application is in the final review stage. We are looking forward to beginning production at the facility and building value for our shareholders, the City of Laval, and Province of Quebec.”

MYM has retained the services of Cannabis Compliance Inc. to consult the Company on regulatory compliance and due diligence for all its ACMPR projects in Canada.

About Cannabis Compliance Inc.
Cannabis Compliance Inc. (CCI) offers risk mitigation, due diligence and regulatory compliance for commercial cannabis producers and resellers around the world. They focus on the Global market and provide their clients with trusted and comprehensive solutions. CCI has extensive expertise in regulatory compliance, cultivation/horticulture, security designs/tender, facility designs/build-outs, quality assurance, training programs, auditing, Good Production Practices (GPP), Good Manufacturing Practices (GMP), Good Agricultural and Collection Practices (GACP), Import & Export, staff recruitment and financial planning. CCI exists to empower the future leaders in the global cannabis industry.

About MYM Nutraceuticals Inc.

MYM Nutraceuticals Inc. is an innovative company focused on acquiring Health Canada licenses to produce and sell high-end organic medicinal cannabis supplements and topical products.  MYM has two production projects in Quebec that when completed will have over 1.5 million sf of production space. MYM is also a partner in a 1.2 million sf production project (Northern Rivers Project) in New South Wales, Australia. Australia is an exciting new market that has recently legalized medicinal cannabis. To ensure a strong presence and growth potential within the industry, MYM is actively looking to acquire complementary businesses and assets in the technology, nutraceuticals and CBD sectors.  MYM shares trade in Canada, Germany and the USA under the following symbols: (CSE: MYM) (OTC:MYMMF) (FRA:0MY) (DEU:0MY) (MUN:0MY) (STU:0MY).

ON BEHALF OF THE BOARD

Rob Gietl, CEO
MYM Nutraceuticals Inc.
www.mymarijuana.ca

Investor Relations
Terry Brown
1.855.696.2261
terry@mymarijuana.ca